Several biosimilar versions of Humira, which for years has been the world's best-selling medicine, entered the U.S. market over the past year. What has that meant for insurance coverage and the way drug makers are marketing these medicines?
This March, join STAT'S Ed Silverman, Pharmalot columnist and senior writer, alongside leading experts to discuss the impact of biosimilars on patients and the healthcare industry.
Meet the Panel:
Madelaine A. Feldman, M.D., FACR, vice president of advocacy and government affairs, Coalition of State Rheumatology Organizations; clinical assistant professor of medicine, Tulane University School of Medicine
Michael Gonzales, independent health care consultant, Michael Gonzales, LLC; former national and regional account director, AbbVie
No comments